Palvella Therapeutics, Inc. $PVLA Stock: Royce & Associates LP Grows Stake

Royce & Associates LP grew its stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) by 24.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,509 shares of the company’s stock after purchasing an additional 10,000 shares during the quarter. Royce & Associates LP owned approximately 0.35% of Palvella Therapeutics worth $6,967,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. KBC Group NV purchased a new position in Palvella Therapeutics in the 1st quarter worth about $28,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Palvella Therapeutics in the 2nd quarter valued at about $35,000. Sterling Capital Management LLC boosted its position in Palvella Therapeutics by 907.7% in the 3rd quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock valued at $54,000 after buying an additional 354 shares during the period. Archer Investment Corp purchased a new stake in Palvella Therapeutics in the 2nd quarter valued at about $69,000. Finally, Quantbot Technologies LP bought a new position in Palvella Therapeutics in the 2nd quarter worth about $71,000. 40.11% of the stock is currently owned by institutional investors.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $146.58 on Thursday. Palvella Therapeutics, Inc. has a one year low of $72.22 and a one year high of $179.95. The firm has a market cap of $2.14 billion, a P/E ratio of -26.65 and a beta of -0.21. The firm has a 50-day simple moving average of $143.05 and a 200-day simple moving average of $130.96.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.08. On average, research analysts predict that Palvella Therapeutics, Inc. will post -6.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PVLA shares. Oppenheimer raised their target price on shares of Palvella Therapeutics from $210.00 to $232.00 and gave the stock an “outperform” rating in a research report on Friday, November 6th. William Blair initiated coverage on Palvella Therapeutics in a report on Friday, October 16th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Friday, September 25th. Leerink Partners began coverage on Palvella Therapeutics in a report on Monday. They set an “outperform” rating and a $228.00 price objective on the stock. Finally, Canaccord Genuity Group lifted their target price on Palvella Therapeutics from $232.00 to $243.00 and gave the company a “buy” rating in a research report on Monday, November 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Palvella Therapeutics presently has an average rating of “Buy” and an average price target of $214.86.

View Our Latest Analysis on PVLA

Insider Buying and Selling at Palvella Therapeutics

In related news, Director George Jenkins sold 7,174 shares of the business’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total transaction of $935,202.64. Following the completion of the transaction, the director directly owned 139,790 shares in the company, valued at $18,223,024.40. The trade was a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Kiritsy sold 313 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the sale, the director directly owned 250 shares in the company, valued at $39,250. This represents a 55.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 63,004 shares of company stock valued at $9,145,763 over the last quarter. Insiders own 17.20% of the company’s stock.

About Palvella Therapeutics

(Free Report)

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.

Read More

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report).

Institutional Ownership by Quarter for Palvella Therapeutics (NASDAQ:PVLA)

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.